CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

Right arrow Help viewing high resolution images
Right arrow Return to article


Fig. 3. Expression of PPAR-{gamma}1 and PPAR-{gamma}2 isoforms in human prostate cancer cell lines showing the effect of 15d-PGJ2 treatment. a, cells were treated with 2.5 and 10 µM 15d-PGJ2 and harvested at 3-, 6-, and 24-h intervals. Western blots were prepared and probed with anti-PPAR-{gamma} antibody (1:2000; BioMol), which detects both isoforms of PPAR-{gamma}. b, Western blots of benign (B) and cancerous (T) prostate tissue, DU145 cells treated with 10 µM 15d-PGJ2 for 6 h, and differentiated 3T3-L1 cells. The same antibody shown in a was used in b.





Right arrow Return to article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation